Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?

Keiichi Fujiwara, Katsuyuki Kiura, Kenichi Gemba, Yoshiko Ogata, Katsuyuki Hotta, Daizo Kishino, Masahiro Tabata, Hiroshi Ueoka, Mitsune Tanimoto

Research output: Contribution to journalArticle

4 Citations (Scopus)


Gefitinib ('Iressa', ZD1839) has promising antitumor activity in non-small cell lung cancer (NSCLC). However, patients with advanced NSCLC have few treatment options available if they are refractory to gefitinib. We describe four cases of patients with advanced NSCLC who previously responded to gefitinib and obtained significant tumor regression through retreatment with other cytotoxic agents. Gefitinib might restore chemosensitivity to previously chemorefractory patients.

Original languageEnglish
Pages (from-to)547-549
Number of pages3
JournalAnticancer research
Issue number1 B
Publication statusPublished - Jan 1 2005


  • Gefitinib ('Iressa', ZD1839)
  • Non-small cell lung cancer (NSCLC)
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?'. Together they form a unique fingerprint.

  • Cite this

    Fujiwara, K., Kiura, K., Gemba, K., Ogata, Y., Hotta, K., Kishino, D., Tabata, M., Ueoka, H., & Tanimoto, M. (2005). Gefitinib ('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients? Anticancer research, 25(1 B), 547-549.